Tamoxifen is a prodrug widely used in the treatment of breast cancer, but the patient response to it depends on their ability to metabolize it into endoxifen. Researchers have developed a new method that allows, through a ...
Mar 25, 2015
0
12
Immunotherapies, such as anti-PD-1 and anti-PD-L1, have become standard first line therapies for patients with advanced renal cell carcinoma (kidney cancer). Most patients, however, eventually experience disease progression, ...
Apr 3, 2023
0
4
A study conducted at Nationwide Children's Hospital has found that a new chemotherapy is effective against both pediatric and adult cancers, and that it allows other chemotherapies to more readily reach their targets. The ...
Jul 27, 2016
0
4
Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with ...
Jun 3, 2013
0
1
"Juicing" Th17 cells with FDA-approved small molecule β-catenin and p110δ inhibitors during in vitro expansion for adoptive T cell therapy (ACT) profoundly improves their therapeutic properties, report investigators at ...
May 8, 2017
0
8
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor-positive ...
Dec 6, 2023
0
1
(HealthDay)—The novel cell cycle inhibitor selective for the cyclin-dependent kinases CDK4 and CDK6 (CDK4/6), LY2835219, shows promise for metastatic breast cancer, according to a study presented at the annual meeting of ...
Apr 7, 2014
0
0
Garden soil houses a variety of bacteria and their natural byproducts—including one that may help halt tumor growth. Lankacidins are molecules that can be isolated from Strepomyces rochei, a common bacterium in soil. In ...
Jan 31, 2022
0
40
(HealthDay)—The orally bioavailable tyrosine kinase inhibitor cabozantinib (XL184) has clinical activity in men with castration-resistant prostate cancer (CRPC), according to a study published online Nov. 19 in the Journal ...
Dec 3, 2012
0
0
(HealthDay)—The monoclonal antibody against epidermal growth factor receptor (EGFR), cetuximab, augments the antitumor activity of paclitaxel in patients with previously treated urothelial cancer, according to a study published ...
Aug 29, 2012
0
0
